TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Factors Responsible for the Effectiveness of the Lund De-airing Technique

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients planned for aortic valve replacement with or without coronary vein bypass grafts~Exclusion Criteria:~* Significant chronic obstructive pulmonary disease and emphysema~* Previous history of thoracic or cardiac surgery~* Patients requiring internal mammary artery harvesting~* Unilateral or bilateral pulmonary adhesions to chest wall~* Previous radiation to the chest~Intraoperative Exclusion Criteria:~* Inability to obtain adequate bilateral Trans-cranial Echo-doppler signals~* Adherent pleurae~* Accidental opening of the pleurae

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Open pleurae & conventional filling of heart (Type: EXPERIMENTAL): In this group both pleurae will be opened and the ventilator disconnected during cardiopulmonary bypass to ensure bilateral pulmonary collapse. However, after completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine and manual de-airing performed in a conventional manner and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is complete and patient has been weaned off the cardiopulmonary bypass the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
- Intact pleurae & staged filling of heart (Type: EXPERIMENTAL): In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: DEFINED_POPULATION
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patient aged \> 18 years~* Admitted to an ICU with an expected ICU length of stay \> 72 hours~* Severe renal insufficiency, defined by a calculated CrCl \< 30 mL/min/1.73m2~Exclusion Criteria:~* ICU admission for \> 2 weeks at time of screening~* ICU admission within 3 months of cardiac surgery or neurosurgery~* Active bleeding or at high risk for bleeding complications~* Thrombocytopenia (platelet count \< 75 x 10\^9/L) at time of screening~* Coagulopathy (International Normalized Ratio \[INR\] or activated partial thromboplastin time \[aPTT\] \> 2 times upper limit of normal) at time of screening~* Patient had an indwelling epidural catheter for epidural analgesia within the last 12 hours~* Receipt of \> 2 doses of LMWH (prophylactic- or therapeutic-dose) in the ICU~* Receiving or requiring therapeutic-dose anticoagulation (eg., deep vein thrombosis \[DVT\]) at time of screening~* Receiving dialysis that requires anticoagulation (eg., PRISMA, slow continuous ultrafiltration \[SCUF\]) at time of screening~* Weight \< 45 kg~* Woman who is pregnant or lactating~* Bilateral lower limb amputation~* Previous adverse reaction to heparin or LMWH (eg., allergy, heparin-induced thrombocytopenia \[HIT\])~* Contraindication to receiving blood products~* Life expectancy \< 14 days or receiving palliative care~* Prior enrolment in this study or enrolment in a concurrent related clinical trial~* Patient or surrogate decision-maker does not provide consent to participate in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of metastatic colorectal cancer~* Measurable disease by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) (Appendix 1)~* Adequate haematological, hepatic and renal function~* Age ≥ 18 years~* Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1~* Patients must have recovered from effects of any recent major surgery~* Willing to use contraception if applicable~* Informed consent~* Life expectancy estimated to be more than 12 weeks~Exclusion Criteria:~* Main exclusion criteria~* Contraindications to FOLFOX chemotherapy: Peripheral neuropathy NCI CTC \>1, Liver failure, uncontrolled coronary heart disease, myocardial infarction within the previous 6 months.~* Unwilling or unable to comply with the study protocol.~* Patients who are pregnant or lactating or contemplating pregnancy. Patients or their partners who become pregnant during the study will be referred to the appropriate experts.~* Undergone chemotherapy (other than adjuvant for CRC) or participating in another drug study.~* Previous cancer \<5 years (other than colorectal, basal cell carcinoma, in-situ cervical cancer).~* Major surgery within 4 weeks of starting the study~* Co-existing active infection or serious concurrent medical condition~* Significant cardiovascular disease~* Bone metastases~* Known brain or leptomeningeal metastases~* Surgery or hospital admissions for symptomatic intra-abdominal adhesions~* Active endoscopically proven peptic ulcer disease or colitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy only (Type: ACTIVE_COMPARATOR): Patients receiving up to 12 cycles of therapy. Standard care pathway management.
- Chemotherapy plus curcumin (Type: EXPERIMENTAL): Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of primary tumor and conformed brain metastases by enhanced MRI or CT~* the lesion number is no less than 3; or the tumor volume is no smaller than 6cc; or tumor diameter is no shorter than 3cm; or uncontrolled brain tumor after whole brain radiotherapy(WBRT); or the tumor is adjacent to essential structures of the brain, such as brain stem, optic chiasma, optic tract, etc.~* KPS ≥60，or KPS ≥40 and the limitation of motion is simply caused by brain tumor that is adjacent to the motor function areas.~* Age: 18-75 years old.~* Adequate end-organ function:~WBC≥4.0x109/L Neu ≥ 1.5x109/L Hemoglobin ≥ 110 g/L Platelets ≥100 x109/L Total bilirubin ≤ 1.5x ULN AST and ALT ≤ 1.5x ULN BUN and Cr: within the normal range~Exclusion Criteria:~* Other clinically significant diseases (e.g.myocardial infarction within the past 6 months, severe arrhythmia).~* Unable or unwilling to comply with the study protocol.~* The expected survival time is less than 3 months.~* Patients who are anticipated in other clinical trials of brain metastases.~* Patients who has been treated with SRT in other hospitals~* Pregnant patients or female patients whose HCG is positive~* Unsuitable to participate in study, that in the opinion of the treating physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Refractory Brain Metastases (Type: EXPERIMENTAL): Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Infants were eligible for the study if they were:~* 6-12 weeks postnatal age~* weighed more than 3 kg~* were after surgical repair for EA or CDH~* showed clinical GERD~* were to undergo the 48 hour pH measurements.~Infants were excluded if they were:~* allergic to omeprazole~* participated in other interventional trials~* used medications known to interact with omeprazole.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- Oral omeprazole (Type: NO_INTERVENTION): Standard of care: A single dose of 1 mg/kg orally administered omeprazole.
- Rectal omeprazole (Type: ACTIVE_COMPARATOR): A single dose of 1 mg/kg rectally administered omeprazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Study to Assess the Robustness of the CRC749 Inhaler

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females at least 12 years of age.~2. A clinical diagnosis for at least 12 weeks prior to screening of asthma or COPD and stable treatment.~3. Spirometry following salbutamol showing FEV1 ≥40% of predicted normal and FEV1/FVC ratio \<0.7 for COPD subjects.~4. Spirometry without salbutamol showing FEV1 ≥50% of predicted normal for asthma subjects.~5. Ability to use the CRC749 inhaler.~Exclusion Criteria:~1. Other chronic or active respiratory disorder or symptoms of, or treatment for a COPD or asthma exacerbation during the 28 days preceding screening.~2. History of long QT syndrome or screening ECG with QTcF greater than 480 milliseconds.~3. Current evidence of, or history within the 6 months prior to screening of unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, or myocardial infarction.~4. Subjects in whom Advair(R) Diskus(R) / Seretide(R) Accuhaler(R) are contra-indicated.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MGR001 (Type: EXPERIMENTAL): MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent prior to any study-related procedures are performed~* Men and women 18 years of age or older at the time of informed consent signing~* Intestinal failure resulting in Short Bowel Syndrome~* At least 12 months of continuous PN dependency~* 12 weeks of clinical remission of Crohn's disease (CD) prior to dosing~* PN required at least 3 times weekly~* A stable PN volume for four weeks prior to dosing~Exclusion Criteria:~* History of cancer or clinically significant lymphoproliferative disease with fewer than 5 years documented disease-free state~* Participation in clinical study within 30 days for drug or 90 days for antibody~* Use of native GLP-2 or human growth hormone (HGH) within 6 months of screening~* Use of iv glutamine within 30 days prior to screening~* Use of teduglutide~* CD patients who have been treated with biological therapy within 6 months of screening~* IBD patients who require chronic systemic immunosuppressant therapy~* More than 4 SBS- or PN-related hospitalizations within 12 months of screening~* Unplanned hospitalization within one month of screening~* Pregnant or lactating women~* Body weight \> 88kg~* Body mass index (BMI) \< 15 kg/m2~* Severe hepatic impairment or disturbed renal function~* Female subjects who are not surgically sterile or postmenopausal or who are not using medically acceptable methods of birth control during and for 30 days after the treatment period~* Not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements~* Any condition or circumstance that is the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with the analysis of the study results~* Significant active, uncontrolled, untreated systemic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teduglutide (Type: EXPERIMENTAL): 0.05 mg/kg/day sc dose of teduglutide
- Placebo (Type: PLACEBO_COMPARATOR): Matching subcutaneous dose of placebo to teduglutide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6months or older and \>=5kg~* Sickle cell clinic attendant~* Both males and females~* Agree to abide by the study protocol~* Give informed consent and assent~* Not acutely sick at the time of recruitment~* Not having additional chronic disease~* Hb genotype of SS and SC confirmed by electrophoresis~Exclusion Criteria:~* known allergy to any of the antimalarial drugs use in the trial,~* severe illnesses requiring urgent admission,~* treatment with sulfadoxine-pyrimethamine or mefloquine in the previous 2wks~* patients on cotrimoxazole prophylaxis

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Daily proguanil (Type: ACTIVE_COMPARATOR): Standard policy of a supply of proguanil tablets to be taken daily
- IPT with MQ+AS bimonthly (Type: EXPERIMENTAL): Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
- IPT with SP+AQ bimonthly (Type: EXPERIMENTAL): IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* treatment as outpatient~* arterial hypertension~* treatment with a renin inhibitor, ACE inhibitor, ARB, or without RAS blockade~* informed consent~Exclusion Criteria:~* foreseeable difficulties to perform follow up

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren (Type: None): Patients getting Aliskiren at baseline
- ACE-I/ARB (Type: None): Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
- No RAS-inhibition (Type: None): Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Visual Attention to Text and Pictorial Food Labels: An Eye Tracking Experiment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult aged 18 or older~* Self-identifies as Hispanic or Latino~Exclusion Criteria:~* Less than 18 years old~* Does not identify as Hispanic or Latino~* Has one of the following conditions: (Wears bifocals, glaucoma, permanently dilated pupils, eye implants \[artificial lenses, not contact lenses\], less than 2 eyes, or blindness)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Front of package food label (Type: EXPERIMENTAL): 4 labels (3 sodium labels, 1 control barcode label) are shown on an image of a soup can

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with 20-45 years of age;~2. PUQE score ≥6;~3. 7-14 weeks of gestation with viable fetus inside the uterine cavity confirmed by ultrasound dating;~4. Less than 20% weight loss.~Exclusion Criteria:~1. Having major medical problems such as malignant tumor, acute or subacute severe hepatitis, severe aplastic anemia, idiopathic thrombocytopenic purpura, acute appendicitis, acute pancreatitis, TORCH syndrome, etc~2. Having chronic medical conditions such as poorly controlled diabetes, coronary heart disease, uncontrolled hypertension, etc~3. Coexistence of other diseases that cause vomiting such as infectious disease, gestational trophoblastic disease, etc~4. Having asthma, increased intraocular pressure, narrow-angle glaucoma, narrow peptic ulcer, pyloric obstruction, bladder neck obstruction, etc~5. Taking antiemetics such as vitamin B6, ondansetron, metoclopramide, prednisone, anti-vomiting Chinese medicine, etc., within the past week~6. Receiving conservative treatment such as dietary and lifestyle modification~7. Abnormal physical examination and laboratory tests (minor abnormalities in laboratory tests due to pregnancy vomiting, such as liver function and ions, are acceptable for inclusion)~8. Having mental handicaps or psychological disorders~9. Allergic to doxylamine, other ethanolamine-derived antihistamines, pyridoxine hydrochloride, or any inactive ingredient in diclectin~10. Using monoamine oxidase inhibitors~11. Driving or operating heavy machinery~12. Using alcohol or other central nervous system inhibitors

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Diclectin plus active acupuncture (Type: OTHER): Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) , 2-4 tablets/day) + active acupuncture (30 min /every day).
- Diclectin plus sham acupuncture (Type: OTHER): Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg), 2-4 tablets/day) + sham acupuncture (30 min /every day).
- Placebo plus active acupuncture (Type: OTHER): Diclectin placebo (2-4 tablets/day) + active acupuncture (30 min / every day)
- Placebo plus sham acupuncture (Type: OTHER): Diclectin placebo (2-4 tablets/day) + sham acupuncture (30 min /every day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old.~2. Medical record documentation of recurrent CDI per the study definition, that includes either: a) at least one recurrence after a primary episode and has completed at least one round of standard-of-care oral antibiotic therapy or b) has had at least two episodes of severe CDI resulting in hospitalization within the last year.~3. A positive stool test for the presence of toxigenic C. difficile within 30 days prior to or on the date of enrollment.~4. Is currently taking or was just prescribed antibiotics to control CDI related diarrhea at the time of enrollment.~\[Note: Subject's CDI diarrhea must be controlled (\<3 unformed/loose stools/day) while taking this course of antibiotics\]~Exclusion Criteria:~1. Currently has continued CDI diarrhea despite being on antibiotics prescribed for CDI treatment.~2. Previous fecal transplant~3. History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.~4. Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.~5. Compromised immune system (e.g. immunosuppressed due to a medical condition or medication; current or recent (\< 90 days) treatment with chemotherapy)~6. An absolute neutrophil count of \<1000 cells/µL during screening.~7. Pregnant, breastfeeding, or intends to become pregnant during study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is an suspension of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
- RBX2660 (Type: EXPERIMENTAL): RBX2660 is a rectally administered microbiota suspension in a 0.9% sodium chloride irrigation United States Pharmacopeia (USP) solution and cryoprotectant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete